Stemnovate

Stemnovate operates at the intersection of regenerative medicine and drug discovery, providing innovative platforms for multi-organ modelling and cellular assays. The company leverages stem cell reprogramming, microfluidic devices, and computational modelling to create physiologically relevant human and animal tissue models for pharmaceutical R&D. With a business model centered on services, subscriptions, and product sales, it targets both academic and industry partners to enhance precision medicine and streamline drug development. Its strategic partnerships with leading institutions and a focus on rare disease research position it as a specialized player in the preclinical tools market.

Integrated platform combining ethical biobanking of diverse iPSCs, differentiation into liver/heart/brain cells, 3D multicellular modelling in proprietary microfluidic devices (organ-on-a-chip), biosensing, and computational data analysis for predictive drug metabolism, toxicity, and efficacy studies.

Stemnovate competes in the organ-on-a-chip and advanced cell model space with companies like Emulate, CN Bio, Mimetas, and TissUse, as well as larger CROs and life science tools providers. Its differentiation lies in its integrated approach combining a diverse biobank, multi-organ modelling, and a dedicated data platform.